// App-Quantinova.ai

: Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma.

Researchers

Presenter

  • J. Alberto Maldonado

Principal Investigators

  • Tim F. Greten

  • M. Cecilia Monge B.

Medical Centers

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • National Cancer Institute, National Institutes of Health, Medical Research Scholars Program, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved